Psychedelics: From Breakthrough to Backlash—and Back Again
The story of psychedelic medicine is often told as a heroic one.
In the telling, scientists in the 1950s discovered remarkable therapeutic potential in compounds like LSD, MDMA, and psilocybin. They published hundreds of papers, treated thousands of patients, and were on the verge of transforming psychiatry. Then came the 1960s — countercultural excess, public backlash, and finally the 1970 Controlled Substances Act, which classified most psychedelics as Schedule I and effectively ended the research.
For fifty years, the story goes, this powerful family of medicines sat unused while millions suffered with conditions they might have helped. Now, thanks to a small group of dedicated researchers and a new generation of clinical trials, psychedelics are finally returning to medicine — and not a moment too soon, given the depth of the contemporary mental health crisis.
This narrative is largely true. It's also incomplete. And the parts it leaves out matter.
I want to walk through the actual history of psychedelic medicine — the early promise, the legitimate concerns, the long suppression, the renaissance, and the very real reckoning the field is currently going through. Because the work Path of the Pearl is positioned around — bringing psychedelic-assisted therapy carefully into legitimate clinical practice — depends on being honest about both what these medicines can offer and what's gone wrong, even recently, when they've been used without sufficient care.
The Forgotten Era of Scientific Optimism
The history before the 1970 shutdown is genuinely remarkable.
After Albert Hofmann's accidental discovery of LSD's psychoactive effects in 1943, psychedelics quickly became serious research tools. Through the 1950s and into the 1960s, mainstream universities, hospitals, and pharmaceutical companies investigated their potential. Studies were funded by reputable institutions. Findings were published in respected journals. By some estimates, more than 1,000 papers were published and tens of thousands of patients received psychedelic-assisted treatment during this era.
The early findings were striking, especially for conditions that had been resistant to other treatments. Alcoholism. Severe depression. Anxiety. Trauma. End-of-life distress. Some of the research foreshadowed exactly what later studies have rediscovered: that under the right conditions, psychedelic experiences could produce lasting psychological changes that ordinary treatment had not achieved.
It would be wrong to romanticize this era. The standards of clinical research were less rigorous than they are today. Many studies lacked proper controls. Informed consent was not what it is now. The line between researcher and patient was sometimes blurred. Some of what was called therapy would not pass ethical review today.
But the scientific interest was genuine, and the early signal was real. The compounds were doing something that seemed to matter.
What Actually Went Wrong
The collapse of psychedelic research wasn't driven entirely by politics, though politics was a major factor. The fuller story involves several converging problems.
Excesses outside the lab. Psychedelic use expanded rapidly beyond clinical and research settings in the 1960s. Recreational use grew. Some users had genuinely harmful experiences. Cases of prolonged psychosis, suicide, and psychiatric hospitalization made the news. The medicines that had been used carefully in supervised settings began to be used carelessly in entirely different ones, and the predictable harms followed.
Loss of institutional control. Figures like Timothy Leary moved beyond research and into advocacy, encouraging widespread use. Whatever Leary's other merits, his approach undermined the scientific case. The medicines came to be associated with countercultural rebellion rather than with rigorous medicine.
Genuine policy concerns. Some of the regulatory caution wasn't only political. The early research period had produced cases of harm that hadn't been adequately addressed. The infrastructure for safe administration outside clinical settings didn't exist. Even responsible researchers had concerns about how widely use was spreading and what the consequences might be.
Political opportunism. The Nixon administration's response was clearly political, and the 1970 Controlled Substances Act placed all classical psychedelics in Schedule I — the most restrictive category, with no recognized medical use and severe limitations on research. This designation was disproportionate to the evidence and, in retrospect, has been widely criticized. But it didn't emerge from nothing. It emerged from a combination of real concerns and political calculation.
The consequence was decades of effective research silence. Studies didn't completely stop, but the regulatory and funding barriers made them extraordinarily difficult. Most academic researchers moved to other topics. The compounds remained in clinical memory primarily as something to be cautious about, and the careful clinical work of the previous era was largely lost.
The Cost of the Silence
It's worth pausing on what this silence cost.
For fifty years, while psychedelics sat unused, mental health conditions worsened in many populations. PTSD became increasingly recognized but remained difficult to treat. Treatment-resistant depression affected millions, with limited options after standard medications failed. Addiction continued to devastate communities. Suicide rates rose. Overdose deaths reached crisis levels. Anxiety and depression became, by some measures, the defining mental health challenges of the era.
Meanwhile, pharmaceutical innovation in psychiatry slowed dramatically. The major pharmaceutical companies, frustrated by the high failure rate of psychiatric drug development, scaled back their psychiatric programs. The treatments available in 2020 looked largely similar to the treatments available in 1990, and the people they didn't help remained without options.
Whether or not psychedelics would have closed this gap is impossible to know. The early research, while promising, was not rigorous enough to justify confident claims. But the absence of serious investigation during fifty years of growing mental health crisis represents, at minimum, a missed opportunity to find out.
This is part of what drove the renewed interest beginning in the late 1990s and accelerating through the 2010s. A new generation of researchers, often working at academic institutions like Johns Hopkins, NYU, and Imperial College London, began carefully picking up the work that had been abandoned. The early results were striking. Studies on psilocybin for treatment-resistant depression, end-of-life anxiety, and addiction produced effect sizes that conventional treatments rarely matched.
The psychedelic renaissance was underway.
The Renaissance and Its Cracks
For most of the 2010s, the story was straightforwardly hopeful.
Clinical trials were producing impressive results. The FDA granted Breakthrough Therapy designation to MDMA-assisted therapy for PTSD in 2017 and to psilocybin for depression in 2018. Major academic centers established psychedelic research programs. Investment poured in. Oregon and Colorado moved forward with state-level legalization of psilocybin therapy. The field appeared to be on a steady trajectory toward FDA approval and mainstream integration.
Then, in August 2024, the FDA rejected MDMA-assisted therapy for PTSD.
The rejection was a shock to many in the field. The clinical trials, on their face, had shown impressive results. The need for new PTSD treatments was unquestionable. The expectation, both inside and outside the field, was approval.
The reasons for rejection were sobering. They tell a story the field is still grappling with, and one that anyone considering psychedelic-assisted therapy deserves to know.
Functional unblinding. MDMA produces effects so distinctive that participants and therapists could almost always tell whether they had received the drug or a placebo. This undermines the basic logic of the placebo-controlled trial. The FDA noted that expectancy effects became indistinguishable from pharmacological effects.
Selection bias. Many participants in the trials had used MDMA before and entered expecting benefit. This is a population unlikely to produce regulatory-grade efficacy data.
Standardization problems. The psychotherapy component of the treatment wasn't standardized in a way that would allow it to be reliably reproduced. The MAPS treatment manual incorporated elements from over a dozen different psychotherapeutic approaches, and the FDA noted that this lack of standardization made it difficult to know what would actually be approved.
Adverse events. FDA inspections uncovered unreported adverse events at multiple sites. The agency's review concluded that Lykos had not adequately characterized the drug's safety, acute effects, duration of impairment, or abuse potential.
Ethical violations. Most seriously, allegations of therapist sexual misconduct at a Phase 2 trial site in Canada led to retraction of three peer-reviewed papers in August 2024. The therapist involved was accused of sexually assaulting a research participant during her MDMA experience. The ICER review concluded that sexual boundaries were severely crossed with at least one patient in a Phase II trial. The participant's case has been the subject of extensive reporting and a podcast investigation.
These are not minor concerns. The patient who was harmed had come into the trial seeking help for PTSD. She left having been sexually assaulted by her therapists while in an altered state. The institutional response from MAPS — the organization that conducted the trial — has been the subject of significant criticism, including allegations of inadequate transparency and a culture that allowed boundary violations to go unaddressed.
The Lykos/MAPS situation isn't the entire field. But it points to real problems that the broader psychedelic medicine movement has had to reckon with.
What This Has Taught the Field
The MDMA rejection forced an honest reckoning.
The lessons being absorbed by researchers and clinicians include:
Boundary violations during altered states are uniquely dangerous. Patients under psychedelics are particularly vulnerable. Their judgment is altered, their defenses are softened, their capacity to refuse or report is compromised. Therapist sexual contact is always a serious violation; with patients in psychedelic states it is profoundly so. The field has begun to develop stricter standards, more rigorous training requirements, and better oversight structures — though much work remains.
The therapy component needs to be standardized. If a treatment is going to involve both medicine and psychotherapy, the psychotherapy has to be defined clearly enough that what's being tested can be reliably reproduced. Treatments built around proprietary, multi-approach, hard-to-replicate therapeutic frameworks pose real regulatory and ethical problems.
Adverse events must be reported. Underreporting of difficult experiences and adverse outcomes — out of misplaced enthusiasm for the field, or self-interested protection of the research, or simple inadequate procedures — has been a real problem. The field is now building better infrastructure for honest adverse event reporting.
Functional unblinding is a structural problem. When a drug's effects are obviously different from a placebo, the placebo-controlled trial model breaks down. The field is exploring alternative trial designs, including active placebos and dose-finding approaches, but no full solution has emerged.
Advocacy and science don't mix well. MAPS was both a research organization and an advocacy organization with deep emotional investment in MDMA's approval. The conflict between these roles appears, in retrospect, to have compromised the integrity of the research in ways that were difficult to see from inside the organization.
These lessons matter because the next significant test is approaching. Compass Pathways completed two positive Phase 3 trials of psilocybin for treatment-resistant depression — COMP005 in June 2025 and COMP006 in February 2026. The company is targeting a New Drug Application submission in Q4 2026, with a potential FDA decision in late 2026 or early 2027. Whether psilocybin receives approval — and whether other psychedelic therapies follow — will depend in significant part on whether the field has actually learned what the MDMA rejection was trying to teach it.
What This Means for Where We Are
The honest picture of where psychedelic medicine stands right now is complicated.
The clinical promise remains real. Studies continue to show that psychedelic-assisted therapy can produce changes in conditions like treatment-resistant depression, end-of-life anxiety, and certain addictions that other treatments have not reached. The neuroscience has advanced significantly, and there are now coherent biological models of why these compounds work the way they do.
At the same time, the field is in a real moment of reckoning. The MDMA rejection was not simply a regulatory setback. It surfaced genuine problems — about ethics, about study design, about institutional culture, about how to integrate medicine and psychotherapy responsibly. Some of these problems were always present. Some have grown as the field has expanded into territory it wasn't quite ready for.
State-level legalization adds another layer of complexity. Oregon's Measure 109 and Colorado's Proposition 122 have opened legal psilocybin therapy in those states ahead of federal approval. These programs have produced both genuine help for patients and real concerns about quality control, training standards, and oversight. The infrastructure for safe psilocybin therapy outside the federal regulatory framework is still being built.
Outside the clinic and state programs, an underground ecosystem of retreats, ceremonies, and underground guides continues to operate. Some of this work is careful and helpful. Some is reckless. Some has caused serious harm. The current legal limbo doesn't make this work disappear; it just makes it harder to regulate.
For anyone considering psychedelic-assisted therapy, this means the choice is more complicated than it sometimes appears. Legal access is limited. The quality of available care varies enormously. The field is still figuring itself out. And the marketing — whether from retreat centers, ketamine clinics, or some psychedelic therapists — sometimes overstates what's known.
What Path of the Pearl Stands For
I want to be honest about where this practice sits in this larger picture.
I support careful, responsible development of psychedelic-assisted therapy. I believe the early clinical research and the deeper neuroscience point toward something real. I'm watching the Compass Pathways pipeline with cautious hope, and I'm preparing for what legal psilocybin therapy will require if and when it becomes available in California.
I also believe the field has serious work to do. The MDMA rejection was not unjust. The ethical violations that surfaced are not isolated incidents that can be dismissed. The standards for therapist training, boundary management, informed consent, adverse event reporting, and research integrity need to be substantially higher than they have been. Patients deserve protection precisely because the medicines are powerful and the states they produce are uniquely vulnerable.
What I try to offer at this practice is what I think the field most needs: serious depth-oriented psychotherapy as the foundation, with careful clinical use of the legal psychedelic medicines (currently ketamine) as one tool among many, with rigorous attention to preparation and integration, and with honesty about both the potential and the limits. When psilocybin therapy becomes legally available, I plan to continue this work with the same approach.
What I don't want to be is a participant in the next wave of psychedelic enthusiasm that gets out ahead of what we actually know how to do well. The history we just walked through is a cautionary tale. The field that gets this right will be slower, more careful, and more honest than the one that's been moving most loudly through the last decade.
A Closing Thought
The story of psychedelics is not a simple morality tale of suppression and return. It's a more complicated story about powerful compounds, human institutions, the difficulty of doing good research on subjective experience, and the ways enthusiasm and caution have both, at different times, failed to serve patients.
What's clear is that something real is being studied — that under the right conditions, with the right preparation, in the right relationship, with proper integration, these medicines can help people whose suffering has not yielded to other treatments. What's also clear is that the right conditions is harder to achieve than the field has sometimes acknowledged, and that getting it wrong has real costs to real people.
For anyone considering psychedelic-assisted therapy now or in the future, the most important questions aren't about whether the medicines work. They work, for some people, in some conditions, under the right circumstances. The important questions are about the circumstances. Who is providing the care. What their training and supervision look like. How they handle preparation, the experience itself, and integration. How they think about boundaries, ethics, and harm. Whether they're honest about what they don't know.
The history of this field offers both promise and warning. Both deserve to be heard.
If you'd like to discuss what careful, responsible work in this space could look like for you, you're welcome to book a consultation.